Tafetinib Malate

苹果酸他菲替尼

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameTafetinib Malate
Drug Alias NameSIM-0702SIM-010603SIM-1005
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 2 antagonistsStem cell growth factor receptor inhibitors +[4] 
TargetsStem cell growth factor receptorVascular endothelial growth factor receptor 3Platelet-derived growth factor receptor beta +[4] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Simcere Pharmaceutical Co LtdNanjing Yoko Biomedical Co LtdJilin Boda Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Xiansheng Medicament Research Co LtdJilin Boda Pharmaceutical Co LtdNanjing Simcere Dongyuan Pharmaceutical Co Ltd
Inactive CompaniesNanjing Yoko Biomedical Co Ltd
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A